Advertisement


Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Advertisement